• About
  • Subscribe
  • Advertise
  • Contact
Wednesday, June 18, 2025
Newsletter
SUBSCRIBE
  • Latest News
  • All Sections
    • Ophthalmic insights
      • Policy & regulation
      • Company updates & acquisitions
      • Research
      • Clinical trials
      • Workforce
      • Product approvals
      • Conferences
      • Opinion
      • Indigenous eye health
      • Retail
    • Eye disease
      • Dry eye
      • Myopia
      • Cataract
      • Glaucoma
      • Macular disease – AMD
      • Diabetic eye disease
      • Inherited retinal disease
      • Corneal disease
      • Presbyopia
      • Eye infections
    • Ophthalmic Careers
      • New appointments
      • Industry profiles
      • Graduates
    • Ophthalmic organisations
      • Regulators
      • Optometry networks
      • Private ophthalmology clinics
      • Associations
      • Patient support bodies
      • Eye research institutions
      • Optometry schools
      • Optical Dispensing trainers
      • Medical schools
      • RANZCO
  • Features
    • Report
    • Soapbox
  • Ophthalmic education
    • CPD – Optometry
    • Optical Dispensing
    • Orthoptics Australia
    • Practice management
  • Products
    • Ophthalmic Treatments
      • Ophthalmic lenses
      • Lens treatments
      • Myopia interventions
      • Light-based therapy
      • Minimally invasive glaucoma surgery (MIGS)
      • Gene therapy
      • Laser treatments
      • Supplements
      • Eyewear & frames
      • Behavioural optometry/vision training
      • Contact lenses
      • Anti-VEGF
      • Intraocular lenses (IOLs)
      • Pharmaceuticals & consumables
    • Ophthalmic equipment & diagnostics
      • Biometry – axial length
      • Perimetry & visual fields
      • OCT
      • Phoropter
      • Autorefractor
      • Tonometry
      • Topography
      • Multimodal imaging
      • Retinal imaging
      • Anterior segment imaging
      • Software & data management
      • Microscopes
      • Slit lamps
      • Lens edging
      • Stands, chairs and tables
      • Ultrasound
      • Dry eye diagnostics
      • Low vision aids
  • Research
  • Classifieds
No Results
View All Results
  • Latest News
  • All Sections
    • Ophthalmic insights
      • Policy & regulation
      • Company updates & acquisitions
      • Research
      • Clinical trials
      • Workforce
      • Product approvals
      • Conferences
      • Opinion
      • Indigenous eye health
      • Retail
    • Eye disease
      • Dry eye
      • Myopia
      • Cataract
      • Glaucoma
      • Macular disease – AMD
      • Diabetic eye disease
      • Inherited retinal disease
      • Corneal disease
      • Presbyopia
      • Eye infections
    • Ophthalmic Careers
      • New appointments
      • Industry profiles
      • Graduates
    • Ophthalmic organisations
      • Regulators
      • Optometry networks
      • Private ophthalmology clinics
      • Associations
      • Patient support bodies
      • Eye research institutions
      • Optometry schools
      • Optical Dispensing trainers
      • Medical schools
      • RANZCO
  • Features
    • Report
    • Soapbox
  • Ophthalmic education
    • CPD – Optometry
    • Optical Dispensing
    • Orthoptics Australia
    • Practice management
  • Products
    • Ophthalmic Treatments
      • Ophthalmic lenses
      • Lens treatments
      • Myopia interventions
      • Light-based therapy
      • Minimally invasive glaucoma surgery (MIGS)
      • Gene therapy
      • Laser treatments
      • Supplements
      • Eyewear & frames
      • Behavioural optometry/vision training
      • Contact lenses
      • Anti-VEGF
      • Intraocular lenses (IOLs)
      • Pharmaceuticals & consumables
    • Ophthalmic equipment & diagnostics
      • Biometry – axial length
      • Perimetry & visual fields
      • OCT
      • Phoropter
      • Autorefractor
      • Tonometry
      • Topography
      • Multimodal imaging
      • Retinal imaging
      • Anterior segment imaging
      • Software & data management
      • Microscopes
      • Slit lamps
      • Lens edging
      • Stands, chairs and tables
      • Ultrasound
      • Dry eye diagnostics
      • Low vision aids
  • Research
  • Classifieds
No Results
View All Results
Home Local

Australia shines in EssilorLuxottica APAC business in 2022

by Myles Hume
March 14, 2023
in Business, Company updates & acquisitions, Local, News
Reading Time: 4 mins read
A A
Australia EssilorLuxottica 2022

OPSM was a solid performer while Sunglass Hut grew comparable-store sales by more than a third in 2022.

Share on FacebookShare on Twitter

OPSM and a record year for Sunglass Hut in Australia were standouts within the EssilorLuxottica Asia-Pacific business in 2022, which posted “comparable” revenue of €2.8 billion (AU$4.5 b) against the region’s 2021 performance.

Australia’s strong financial performance comes as the group announced a major renewable energy supply agreement as part of its plan to become carbon neutral in its direct operations by 2025.

In late February, EssilorLuxottica published its full 2022 financial results, with CEO Mr Francesco Milleri announcing record sales of €24.5 billion (AU$39.4 b), with a net profit of €2.2 billion (AU$3.5 b).

Asia-Pacific – EssilorLuxottica’s third biggest region after North America and EMEA –  generated 7.2% more revenue in 2022 compared to 2021 at constant exchange rates (+11.8% at current exchange rates).

“The Direct to Consumer division grew mid-single digit at constant exchange rates driven by Australia, with a solid performance in OPSM and a record year for Sunglass Hut growing comparable-store sales by more than one third,” the company stated.

“Asia-Pacific posted comparable revenue … with Mainland China diluting the otherwise excellent performance of the region. Professional Solutions (wholesale customers) was up high-single digit at constant exchange rates.

“All countries recorded strong growth except Mainland China, where the performance was strongly influenced by the COVID-19 circumstances present at different times during the year. However, despite the volatile environment, the demand for myopia management solutions in the country did not fade and Stellest recorded exponential growth more than doubling sales from the prior year.”

Milleri said in addition to record revenue, the company announced ground breaking product launches and delivered on its “promise of a strong, unified company in 2022”.

“Our late chairman, Leonardo Del Vecchio, would have been proud to see the new heights we reached in every geography and the growing bonds between our people and customers,” he said.

“In 2022, we strengthened our open, collaborative business model, while completing important acquisitions such as Walman in North America and Shamir in Israel, and continuing to invest in quality eyecare and eyewear for the benefit of the entire market. At the same time, we continued to showcase our unique innovation capability, through new sustainable collections and the ongoing deployment of new lens products and categories.”

In the face of ongoing macroeconomic uncertainties, Milleri said the company remained focused on: the vertical integration of the business, the embedding of big data in corporate decisions, its global footprint, and the deployment of its sustainability program ‘Eyes on the Planet’.

“In 2022, we also confirmed our long-term commitment to our mission by launching the largest vision care foundation in the world. All these key factors, combined with our nearly 200,000 talented employees, will enable us to achieve continued growth in the years ahead,” he added.

Green energy agreement 

Meanwhile, EssilorLuxottica and ERG, a leading European producer of energy from renewable sources through its subsidiary ERG Power Generation, have signed a 12-year Power Purchase Agreement (PPA) for the supply of approximately 900 GWh of green energy between 2023-2034.

The agreement is based on the sale by ERG of approximately 75% of the energy produced by its Partinico-Monreale wind farm near Palermo, Italy.

Following the replacement of the entire facility with latest generation equipment, the wind farm will consist of 10 turbines of 4.2 MW with a total installed power of 42 MW (compared to the previous 19 turbines for a 16 MW installed power) and an estimated annual production of 94GWh (compared to the current 27 GWh). The wind farm is in an advanced stage of construction and will come into operation during the second quarter of 2023.

For EssilorLuxottica, this agreement marks an important step towards its objective of becoming carbon neutral in its direct operations (Scope 1 and 2 emissions) by 2025, starting with Europe by the end of the year.

More reading

Essilor targets parents in media campaign to increase myopia awareness

OneSight EssilorLuxottica Foundation expands access to vision care in Townsville

Essilor Vision-R 800 – re-thinking refraction with liquid optics

 

Related Posts

The report calls for $160 million to expand training, and the funding should be linked to targets for undersupplied specialties like ophthalmology. Images: Inside Creative House/Shutterstock.com & Robyn Mackenzie/Shutterstock.com.

Grattan Institute raises red flags over ophthalmology fees, training and supply

by Myles Hume
June 18, 2025

Ophthalmology has an under-supply problem, requires more training capacity and features a significant proportion of practitioners charging patients high or...

The brand is renowned for “signature artisanal craftsmanship and precise engineering”. Image: Safilo.

Safilo launches Stuart Weitzman eyewear in Australia

by Staff Writer
June 17, 2025

Stuart Weitzman has expanded its global luxury brand footprint with a first eyewear collection available to Australian independent optical practices...

Studies show only about 17% of people are currently wearing lenses truly matching their visual sensitivity. Image: Rodenstock.

Understanding the concept of ‘visual sensitivity’

by Staff Writer
June 17, 2025

Even when a lens is designed identically for two different people, they can have a polarising visual experience. ALEX RIGBY...

Join our newsletter

View our privacy policy, collection notice and terms and conditions to understand how we use your personal information.

Insight has been the leading industry publication in Australia for more than 40 years. This longevity is largely due to our ability to consistently deliver accurate and independent news relevant to all ophthalmic professionals and their supporting industry.

Subscribe to our newsletter

View our privacy policy, collection notice and terms and conditions to understand how we use your personal information.

About Insight

  • About
  • Advertise
  • Subscribe
  • Contact
  • Terms & Conditions
  • Privacy Collection Notice
  • Privacy Policy

Popular Topics

  • Business
  • Feature
  • Research
  • Technology
  • Therapies
  • Classifieds

© 2025 All Rights Reserved. All content published on this site is the property of Prime Creative Media. Unauthorised reproduction is prohibited

No Results
View All Results
NEWSLETTER
SUBSCRIBE
  • Latest News
  • All Sections
    • Ophthalmic insights
      • Policy & regulation
      • Company updates & acquisitions
      • Research
      • Clinical trials
      • Workforce
      • Product approvals
      • Conferences
      • Opinion
      • Indigenous eye health
      • Retail
    • Eye disease
      • Dry eye
      • Myopia
      • Cataract
      • Glaucoma
      • Macular disease – AMD
      • Diabetic eye disease
      • Inherited retinal disease
      • Corneal disease
      • Presbyopia
      • Eye infections
    • Ophthalmic Careers
      • New appointments
      • Industry profiles
      • Graduates
    • Ophthalmic organisations
      • Regulators
      • Optometry networks
      • Private ophthalmology clinics
      • Associations
      • Patient support bodies
      • Eye research institutions
      • Optometry schools
      • Optical Dispensing trainers
      • Medical schools
      • RANZCO
  • Features
    • Report
    • Soapbox
  • Ophthalmic education
    • CPD – Optometry
    • Optical Dispensing
    • Orthoptics Australia
    • Practice management
  • Products
    • Ophthalmic Treatments
      • Ophthalmic lenses
      • Lens treatments
      • Myopia interventions
      • Light-based therapy
      • Minimally invasive glaucoma surgery (MIGS)
      • Gene therapy
      • Laser treatments
      • Supplements
      • Eyewear & frames
      • Behavioural optometry/vision training
      • Contact lenses
      • Anti-VEGF
      • Intraocular lenses (IOLs)
      • Pharmaceuticals & consumables
    • Ophthalmic equipment & diagnostics
      • Biometry – axial length
      • Perimetry & visual fields
      • OCT
      • Phoropter
      • Autorefractor
      • Tonometry
      • Topography
      • Multimodal imaging
      • Retinal imaging
      • Anterior segment imaging
      • Software & data management
      • Microscopes
      • Slit lamps
      • Lens edging
      • Stands, chairs and tables
      • Ultrasound
      • Dry eye diagnostics
      • Low vision aids
  • Research
  • Classifieds
  • About Us
  • Advertise with Insight
  • Subscribe
  • Contact Insight

© 2025 All Rights Reserved. All content published on this site is the property of Prime Creative Media. Unauthorised reproduction is prohibited